HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|17|1|33-45

ISSN： 1389-4501

Source： Current Drug Targets, Vol.17, Iss.1, 2016-01, pp. : 33-45

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Contributions of HIV-1 Nef to immune dysregulation in HIV-infected patients: a therapeutic target?

By Witkowski Wojciech   Verhasselt Bruno  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 11, 2013-11 ,pp. : 1345-1356

Informa Healthcare

Access to resources Recommend Favorite

The HIV-1 Tat Protein: A Multifaceted Target for Novel Therapeutic Opportunities

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 4, Iss. 4, 2004-12 ,pp. : 277-285

Bentham Science Publishers

Access to resources Recommend Favorite

HIV-1 Integrase: A Target for New AIDS Chemotherapeutics

By  

Current Topics in Medicinal Chemistry, Vol. 4, Iss. 9, 2004-05 ,pp. : 979-990

Bentham Science Publishers

Access to resources Recommend Favorite

HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions

By  

Current Drug Targets, Vol. 17, Iss. 1, 2016-01 ,pp. : 4-14

Bentham Science Publishers

Access to resources Recommend Favorite

Virus maturation as a new HIV-1 therapeutic target

By Adamson Catherine S   Salzwedel Karl   Freed Eric O  

Expert Opinion on Therapeutic Targets, Vol. 13, Iss. 8, 2009-08 ,pp. : 895-908

Informa Healthcare

Access to resources Recommend Favorite